Главная \ Разное \ Scientific research

Scientific research

  • Guryanova S, Udzhukhu V, Kubylinsky A. Pathogenetic Therapy of Psoriasis by Muramyl Peptide. Front Immunol. 2019 Jun 20;10:1275. doi: 10.3389/fimmu.2019.01275

https://www.frontiersin.org/articles/10.3389/fimmu.2019.01275/full


  • Laman AG, Lathe R, Shepelyakovskaya AO, Gartseva A, Brovko FA, Guryanova S, Alekseeva L, Meshcheryakova EA, Ivanov VT.  Muramyl peptides activate innate immunity conjointly via YB1 and NOD2. 2.       Innate Immun. 2016 Nov;22(8):666-673. doi: 10.1177/1753425916668982

https://journals.sagepub.com/doi/pdf/10.1177/1753425916668982


  • Nikitushkin VD, Demina GR, Shleeva MO, Guryanova SV, Ruggiero A, Berisio R, Kaprelyants AS. A product of RpfB and RipA joint enzymatic action promotes the resuscitation of dormant mycobacteria. FEBS J. 2015 Jul;282(13):2500-11. doi: 10.1111/febs.1329

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1111/febs.13292


  • Laman AG, Lathe R, Savinov GV, Shepelyakovskaya AO, Boziev KhM, Baidakova LK, Chulin AN, Brovko FA, Svirshchevskaya EV, Kotelevtsev Y, Eliseeva IA, Guryanov SG, Lyabin DN7, Ovchinnikov LP, Ivanov VT. Innate immunity: Bacterial cell-wall muramyl peptide targets the conserved transcription factor YB-1. FEBS Lett. 2015 Jul 8;589(15):1819-24. doi: 10.1016/j.febslet.2015.05.028

https://febs.onlinelibrary.wiley.com/doi/full/10.1016/j.febslet.2015.05.028


  • Savinov GV, Shepelyakovskaya AO, Boziev KhM, Brovko FA, Laman AG. Search for ligand of N-acetylglucosaminyl-N-acetylmuramyl dipeptide using its peptide mimetic. Biochemistry (Mosc). 2014 Feb;79(2):131-8. doi: 10.1134/S0006297914020060

http://protein.bio.msu.ru/biokhimiya/contents/v79/full/79020178.html


  • Antsiferova Y, Sotnikova N, Parfenyuk E. Different effects of the immunomodulatory drug GMDP immobilized onto aminopropyl modified and unmodified mesoporous silica nanoparticles upon peritoneal macrophages of women with endometriosis. Biomed Res Int. 2013;2013:924362. doi: 10.1155/2013/924362

https://www.hindawi.com/journals/bmri/2013/924362/


  • Valyakina TI1, Komaleva RL, Petrova EE, Malakhov AA, Shamborant OG, Andronova TM, Nesmeyanov VA.  Endogenous tumour necrosis factor-alpha sensitise melanoma cells to glucosaminylmuramyl dipeptide. FEBS Lett. 1998 Apr 24;426(3):373-6.

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/S0014-5793%2898%2900376-7


  • Golovina TN, Sumaroka MV, Samokhvalova LV, Shebzukhov YuV, Andronova TM, Nesmeyanov VA. Biochemical characterization of glucosaminylmuramyldipeptide binding sites of murine macrophages. FEBS Lett. 1994 Dec 12;356(1):9-12. 

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/0014-5793%2894%2901219-9


  • Mareeva TYu1, Kotova OV, Golovina TN, Nesmeyanov VA. Production and characterization of monoclonal anti-idiotypic antibodies to muramylpeptide. FEBS Lett. 1994 Dec 12;356(1):13-6.

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/0014-5793%2894%2901220-2


  • Sumaroka MV1, Litvinov IS, Khaidukov SV, Golovina TN, Kamraz MV, Komal'eva RL, Andronova TM, Makarov EA, Nesmeyanov VA, Ivanov VT. Muramyl peptide-binding sites are located inside target cells. FEBS Lett. 1991 Dec 16;295(1-3):48-50.

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/0014-5793%2891%2981381-H


  • Kaydalov AA, Utkin YuN, Andronova TM, Tsetlin VI, Ivanov VT. Muramyl peptides bind specifically to rat brain membranes.FEBS Lett. 1989 May 8;248(1-2):78-82.

https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/0014-5793%2889%2980435-1